Earned, Owned and Social Media Analytics Leaders Partner To Help Companies Understand The Business Impact of Content
2.2.2021 19:54:00 EET | Business Wire | Press release
Onclusive, the data science company for communications, and Shareablee, the social media analytics and competitive benchmarking company, today announced their strategic partnership to offer marketing and communications teams best-in-class solutions for earned, owned and social media insights. The partnership will help companies gain more holistic data about the performance of their owned and earned content across global news outlets, influencers and social media platforms.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210202005915/en/
Click to Tweet: Just announced: @Onclusive and @Shareablee partner to help companies measure the business impact of earned, owned, and social media marketing - through to revenue! https://bit.ly/39DF9xE #socialmediamarketing #prmeasurement
Social media, communications, public relations, and marketing teams each have a view of a company’s brand, reputation, and influence. Companies are increasingly looking to measure their owned and earned media strategies in a more centralized way by combining these functions within integrated teams and equipping them with comparable tools.
Particularly during times of crisis or uncertainty when companies put their emphasis on the tactics they can more closely control, social media amplification and paid media activation become even more important, as does measurement of the business impact of these efforts. The intersection between the data and solutions from Onclusive and Shareablee will provide organizations with more comprehensive content marketing data to better optimize their strategies.
Both Onclusive and Shareablee have their roots in enterprise media monitoring and content measurement and support Fortune 100 companies and their agencies. Both companies also recently launched mid-market products to deliver their data, platforms and services to a wider range of organizations.
“Social media strategies are fundamental to a company’s marketing plan, yet there is still more to the story. We are excited to be able to complete the picture for our clients via our relationship with Onclusive,” said Tania Yuki, CEO of Shareablee.
“We’ve always viewed our data and platforms as a bridge between communications teams and marketing teams. By working with Shareablee, our joint clients will be even better equipped to plan and execute harmonious cross-functional brand and communications strategies,” said Dan Beltramo, CEO of Onclusive.
About Onclusive
Onclusive is the data science company for communications. The inventors of PR Attribution™ and Power of Voice™, Onclusive measures the true impact that content is having on a company’s bottom line. The Onclusive platform is built upon a proprietary newscrawler which analyzes millions of earned, owned, and newswire articles every day globally and in over 100 languages, organizing each piece of content based on dozens of dimensions for aggregate and entity-level analysis.
The world’s leading brands and agencies including Airbnb, H&R Block, Lyft, Intercontinental Hotels Group, 23andMe, and Experian use Onclusive to modernize communications. For more information, visit onclusive.com and follow us on Twitter, LinkedIn, and Facebook.
About Shareablee
Shareablee is the leader in audience-based social media measurement for media publishers, agencies and brands that want to understand the impact and effectiveness of their cross-platform social media campaigns. Launched in 2013, Shareablee empowers brands by providing data that can help them define and drive success on social media by arming them with metrics and predictive analytics that inform powerful best practices. Shareablee is the leading authority on audience intelligence, competitive benchmarking and actionable insights with clients in 15+ countries.
For more information about Shareablee, visit shareablee.com and follow us on Twitter, LinkedIn, and Facebook.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210202005915/en/
Contact information
Onclusive Contact:
Sean O'Neal
+1 415-906-5938
info@onclusive.com
Shareablee Contact:
Madison Busick
+1 508-868-4461
marketing@shareablee.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 17:00:00 EEST | Press release
PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpinned by global capacity, technical expertise, deep scientific knowledge, and an industry-leading quality and regulatory track record. This press release features multimedia. View the full release here: https://www.
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 16:53:00 EEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 16:00:00 EEST | Press release
Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world. “Data is only valuable when it’s activated,” said Steve Lucas, Chairman and CEO, Boomi. “At Boomi World 2026, we
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 16:00:00 EEST | Press release
Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level in our clients’ complex matters,” said Jeny Maier, managing partner
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 16:00:00 EEST | Press release
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug conjugates (ADCs). Central to Araris’ approach is its proprietary AraLinQ™ ADC technology, which enables the creation of stable and site-specific ADCs using standard antibodies with scalable manufacturing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
